{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P31639",
      "entity_text" : "sodium-glucose cotransporter 2",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:11949646",
      "entity_text" : "empagliflozin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "As well known, empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2), and in EMPA-REG OUTCOME its cardiovascular safety was tested in a population of patients with type 2 diabetes at high cardiovascular risk no different from that of the population in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS), which showed no cardiovascular benefit.",
  "reading_complete" : "2020-07-28T16:25:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T16:24:07Z",
  "trigger" : "inhibits",
  "evidence" : [ "empagliflozin inhibits sodium-glucose cotransporter 2" ],
  "pmc_id" : "5013718",
  "score" : 0
}